New Study: Options After Anti-TNF Failure In RA
This article was originally published in Scrip
Executive Summary
Doctors participating in a new, small study reviewed a Slovenian patient registry in an attempt to answer a long-unanswered question for rheumatoid arthritis patients: After failing to respond or following a short-lived response to tumor necrosis factor (TNF) inhibitors, such as the AbbVie Inc. blockbuster Humira (adalimumab) or Amgen Inc.'s Enbrel (etanercept), is second-line treatment with another anti-TNF therapy the best option or should other mechanisms of action be considered?